RxDoctor Payments Data

Maryanne Horta, MD

Endocrinology, Diabetes & Metabolism · Trumbull, CTNPI 1124209101

Payments from drug & device makers

$1,145in general payments, 2019–2025

Across 44 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$649
  • Amgen$272
  • AbbVie$118
  • Novo Nordisk$41
  • Medtronic$35
  • Lilly USA, LLC$29

What the payments were for

  • Food & beverage$1,10496%
  • Education$424%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott33$649
Amgen5$272
AbbVie1$118
Novo Nordisk2$41
Medtronic1$35
Lilly USA, LLC2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,145 in reported general payments places this provider in the 50th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut

Medicare billing

Part B allowed, 2024
$211,797
Medicare patients
338
Services billed
8,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide479$820,105
OzempicSemaglutide334$610,447
JardianceEmpagliflozin240$300,318
JanuviaSitagliptin Phosphate70$101,612
Tresiba Flextouch U-200Insulin Degludec95$93,666
FarxigaDapagliflozin Propanediol66$93,401
TrulicityDulaglutide33$75,016
Humulin R U-500 KwikpenInsulin Regular, Human49$67,758
Tresiba Flextouch U-100Insulin Degludec119$67,322
Synjardy XrEmpagliflozin/Metformin Hcl29$51,859
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/725$48,874
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog56$39,983
TymlosAbaloparatide13$37,817
ProliaDenosumab20$35,332
Lyumjev Kwikpen U-100Insulin Lispro-Aabc23$29,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$29$905,827551 claims
Novo NordiskOzempic, Wegovy$41$629,666347 claims
AmgenProlia$272$35,33220 claims
AbbVieSynthroid$118$8,67880 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

Other endocrinology, diabetes & metabolism in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →